Reactogenicity and Immunogenicity of Vaginal CNgp140 (SG06RS02)
Phase I Clinical Trial in Healthy Female Volunteers of Reactogenicity and Immunogenicity of Nine Vaginal Immunisations With HIV CN54gp140 Glycoprotein
Sponsor: Bill and Melinda Gates Foundation
Terminated
IMP expired prior to completion of recruitment
Other terminated trials from Bill and Melinda Gates Foundation
Other Acquired Immune Deficiency Syndrome trials with similar outcome
This PHASE1 trial investigates Acquired Immune Deficiency Syndrome and HIV Infections and is currently terminated or withdrawn. Bill and Melinda Gates Foundation leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bill and Melinda Gates Foundation
- St George's, University of London
- York Hospitals
For direct contact, visit the study record on ClinicalTrials.gov .